Q32 Bio Inc. — Director's Dealing 2020

Jun 12, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Homology Medicines, Inc. (FIXX)
CIK: 0001661998
Period of Report: 2020-06-10

Reporting Person: REICIN ALISE (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-06-10	Option (Right to Buy)	$16.32	A	18000	Acquired	2030-06-10	Common Stock (18000)	Direct

Footnotes

F1: This option shall vest and become exercisable on the earlier of June 10, 2021 or the day immediately prior to the date of the next annual meeting of the Company's stockholders occurring after the date of grant, in either case subject to the Non-Employee Director continuing in service on the Board as a Non-Employee Director through such vesting date.